Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' [Seeking Alpha]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Seeking Alpha
REC-4881's efficacy in FAP is unremarkable versus Celebrex, with uncertain regulatory and adoption prospects. RXRX's oncology pipeline, including REC-617 and REC-3565, faces intense competition and lacks meaningful differentiation or near-term catalysts. Milestone-driven partnership revenue is lumpy and insufficient to offset persistent $100M quarterly losses; cash runway extends into early 2028. Thanadon Naksanee/iStock via Getty Images Overview My last look at Recursion Pharmaceuticals ( RXRX ) followed Phase 1/2 data on REC-4881 in familial adenomatous polyposis, or FAP. Recursion became a "household name" in 2023 within pharma and tech investment circles after Nvidia ( NVDA This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented here, including
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswire
- Recursion Pharmaceuticals May Be Losing Ground To Its Peers [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities [Yahoo! Finance]Yahoo! Finance
- Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast [Yahoo! Finance]Yahoo! Finance
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form SCHEDULE
- 4/22/26 - Form 144
- RXRX's page on the SEC website